 OncoSec Medical Incorporated Nasdaq:ONCS the Company or OncoSec, a company developing late-stage intratumoral cancer immunotherapies, today announced the European Medicines Agency EMA issued an advanced therapy medicinal product ATMP certificate for chemistry manufacturing controls CMC data covering its lead product candidate, TAVOTM interleukin-12 or IL-12 plasmid, for the treatment of metastatic melanoma. Following TAVOs classification as an ATMP last year, the certification procedure involved a thorough scientific evaluation over several months of CMC data for TAVO by the EMAs Committee for Advanced Therapies CAT. The CAT assessment of the TAVO CMC data provides valuable regulatory feedback to help ensure a successful marketing authorization application prior to submission. After a positive opinion from CAT, EMA issued a certificate confirming that the CMC data comply with the standards that apply for evaluating the Marketing Authorization Application MAA. 